- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06194318
First-in-human Safety and Immunogenicity Study of SCB-1019 in Healthy Adults
February 20, 2024 updated by: Clover Biopharmaceuticals AUS Pty Ltd
A Phase 1, Placebo-controlled, Randomized, Observer-blind, First-in-human Study to Describe the Safety, Reactogenicity and Immunogenicity of SCB-1019 in Healthy Adults
This phase 1 study in Australia will evaluate the safety, reactogenicity and immunogenicity of the bivalent SCB-1019 vaccine candidate with or without aluminium hydroxide in young adults (18-59 years) and older adults (60-85 years).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study design includes an age- and dose-escalation (low/high dose) in two adult age groups (young adults [18-59 years] and older adults [60-85 years]).
Study will be conducted in two parts, part 1 will enrolled young adults and part 2 will enroll older adults.
A sentinel dosing approach will be used for close monitoring of safety to minimize risk to participants.
Detailed characterization of safety (including safety laboratory evaluation) and immune responses is planned.
A placebo will be used as a control.
The sample size for this study is not based on formal statistical hypothesis testing but is acceptable for safety and immunogenicity evaluation in a phase 1 study.
The study will be overseen by a safety monitoring committee.
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: xuesong pei, MD
- Phone Number: 18515445890
- Email: xuesong.pei@cloverbiopharma.com
Study Contact Backup
- Name: chuanna dou
- Email: chuanna.dou@cloverbiopharma.com
Study Locations
-
-
Southern Australia
-
Adelaide, Southern Australia, Australia, 5067
- Recruiting
- Fusion Clinical Research
-
Contact:
- Christopher D Rook, MD
- Phone Number: 448448543
- Email: christopher.rook@cmax.com.au
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Recruiting
- Linear Clinical Research
-
Contact:
- Ana Liza Sun, Dr
- Phone Number: 0863825100
- Email: asun@linear.org.au
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Male and female participants 18 to 59 years of age (Part 1) and 60 to 85 years of age (Part 2) at the screening visit.
- Individuals willing and able to comply with study requirements, including all scheduled visits, vaccination, laboratory tests, and other study procedures.
- Individuals willing and able to give an informed consent, prior to screening.
- Healthy participants as determined by medical history, physical examination, and clinical judgment of the investigator; participants with pre-existing stable medical conditions can be included (a stable medical condition is defined as a disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment).
- Female of childbearing potential willing to use a highly effective contraceptive method from 30 days before until 90 days after vaccination and have a negative pregnancy test on the day of vaccination; males able to father children and willing to use a highly effective contractive method from vaccination up to 90 days after vaccination, and agree to refrain from donating sperm during this period.
Exclusion Criteria:
- Acute disease or fever (≥38°C) at time of vaccination. Participants with a minor illness (mild diarrhea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator. For participants with minor illness and/or fever at the time of vaccination, Visit 1 may be rescheduled within the allowed time-window.
- History of a severe adverse reaction associated with a vaccine or severe allergic reaction (e.g., anaphylaxis) to any component of the study vaccines.
- Previous vaccination with an RSV vaccine at any time before vaccination (Day 1), or planned receipt during the study of a non-study RSV vaccine.
- Receipt of any other licensed vaccines within 14 days before vaccination (Day 1) or planned receipt of any vaccine up to 28 days after study vaccination (Day 29).
- Receipt of any other investigational product within 30 days before vaccination (Day 1) or intention to participate in another clinical study at any time during the conduct of this study.
- Any condition that, in the opinion of the investigator, would interfere with the primary study objectives or pose additional risk to the participant.
- Receipt of intravenous immunoglobulins and/or any blood products within 60 days before vaccination (Day 1) or planned administration during the study period.
- Individuals with positive test result for hepatitis B surface antigen, hepatitis C virus antibody, and/or human immunodeficiency virus types 1 or 2 antibodies at screening.
- Immunocompromised with known or suspected immunodeficiency, as determined by medical history and/or laboratory/physical examination (no laboratory testing required).
- Receipt of any immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, e.g. for cancer, organ transplantation or autoimmune disease, within three months prior to vaccination or planned receipt during the study. If a short-term course of systemic corticosteroids (<14 days) has been administered for treatment of an acute illness, participants should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before study vaccination. Inhaled/nebulized, intraarticular, intrabursal, or topical (skin or eye) corticosteroids are permitted.
- Treatment with rituximab or any other anti-CD20 monoclonal antibodies within nine months prior to vaccination or planned during the study period.
- History of malignancy within one year before vaccination (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix which has been cured, or other malignancies with minimal risk of recurrence).
- Any screening safety laboratory values (hematology, biochemistry, coagulation, and urinalysis) that meet the definition of a ≥Grade 1 abnormality (according to the toxicity grading)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: group 1 (SCB-1019 90µg with Alum; young adults)
4 young adults (18-59 years old) will receive low dose SCB-1019 (90µg, with Alum) at Day 1
|
The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B).
SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
|
Placebo Comparator: group 2 (Placebo; young adults)
2 young adults (18-59 years old) will receive Placebo at Day 1
|
placebo
|
Experimental: group 3 (SCB-1019 360µg with Alum; young adults)
4 young adults (18-59 years old) will receive high dose SCB-1019 (360µg, with Alum) at Day 1
|
The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B).
SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
|
Placebo Comparator: group 4 (Placebo; young adults)
2 young adults (18-59 years old) will receive Placebo at Day 1
|
placebo
|
Experimental: group 5 (SCB-1019 90µg without Alum; older adults)
10 older adults (60-85 years old) will receive low dose SCB-1019 (90µg, without Alum) at Day 1
|
The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B).
SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
|
Experimental: group 6 (SCB-1019 90µg with Alum; older adults)
10 older adults (60-85 years old) will receive low dose SCB-1019 (90µg, with Alum) at Day 1
|
The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B).
SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
|
Placebo Comparator: group 7 (Placebo; older adults)
4 older adults (60-85 years old) will receive Placebo at Day 1
|
placebo
|
Experimental: group 8 (SCB-1019 360µg without Alum; older adults)
10 older adults (60-85 years old) will receive high dose SCB-1019 (360µg, without Alum) at Day 1
|
The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B).
SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
|
Experimental: group 9 (SCB-1019 360µg with Alum; older adults)
10 older adults (60-85 years old) will receive high dose SCB-1019 (360µg, with Alum) at Day 1
|
The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B).
SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
|
Placebo Comparator: group 10 (Placebo; older adults)
4 older adults (60-85 years old) will receive Placebo at Day 1
|
placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the reactogenicity of SCB-1019 vaccine
Time Frame: Within 7 days after vaccination
|
Proportion of participants with local and systemic solicited AEs
|
Within 7 days after vaccination
|
Evaluate the unsolicited AEs of SCB-1019 vaccine
Time Frame: Within 28 days after vaccination
|
Proportion of participants with unsolicited AEs
|
Within 28 days after vaccination
|
Evaluate the SAEs, AESIs, MAAEs, AEs leading to early termination from the study of SCB-1019 vaccine
Time Frame: Throughout the study period, from enrollment to 6 months follow up
|
Proportion of participants with SAEs, AESIs, MAAEs, AEs leading to early termination from the study
|
Throughout the study period, from enrollment to 6 months follow up
|
Evaluate the safety and tolerability in hematology parameters of SCB-1019 vaccine
Time Frame: Screening and Day 8
|
Mean change and shift from baseline in hematology parameters
|
Screening and Day 8
|
Evaluate the safety and tolerability in biochemistry parameters of SCB-1019 vaccine
Time Frame: Screening and Day 8
|
Mean change and shift from baseline in biochemistry parameters
|
Screening and Day 8
|
Evaluate the safety and tolerability in coagulation parameters of SCB-1019 vaccine
Time Frame: Screening and Day 8
|
Mean change and shift from baseline in coagulation parameters
|
Screening and Day 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Christopher Rook, MD, CMAX Clinical Research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 13, 2023
Primary Completion (Estimated)
October 1, 2024
Study Completion (Estimated)
May 1, 2025
Study Registration Dates
First Submitted
November 17, 2023
First Submitted That Met QC Criteria
January 4, 2024
First Posted (Actual)
January 8, 2024
Study Record Updates
Last Update Posted (Estimated)
February 22, 2024
Last Update Submitted That Met QC Criteria
February 20, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLO-SCB-1019-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Syncytial Virus Infection
-
AbbVie (prior sponsor, Abbott)CompletedRespiratory Syncytial Virus InfectionJapan
-
Janssen Vaccines & Prevention B.V.CompletedRespiratory Syncytial Virus Infection PreventionGermany, Spain, Belgium, Sweden, United States
-
Shanghai Ark Biopharmaceutical Co., Ltd.Ark Biosciences Pty Ltd.CompletedRESPIRATORY SYNCYTIAL VIRUS INFECTIONSAustralia, Hong Kong, Israel, Lebanon, Malaysia, Poland, Taiwan, Turkey
-
PfizerRecruitingRespiratory Syncytial Virus InfectionUnited States, Japan, China, Canada
-
AbbVie (prior sponsor, Abbott)Fundasamin (Argentina)CompletedRespiratory Syncytial Virus InfectionArgentina, Chile, Colombia, Ecuador, Mexico, Peru, Uruguay
-
Vigonvita Life SciencesRecruitingRespiratory Syncytial Virus InfectionChina
-
AbbVie (prior sponsor, Abbott)CompletedRespiratory Syncytial Virus Infection
-
Sanofi Pasteur, a Sanofi CompanyRecruitingHealthy Volunteers | Respiratory Syncytial Virus Infection | Metapneumovirus InfectionAustralia, United States
-
Sanofi Pasteur, a Sanofi CompanyActive, not recruitingRespiratory Syncytial Virus InfectionUnited States, Puerto Rico
-
PfizerCompletedRespiratory Syncytial Virus InfectionChina
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States